Withdrawal of Statins and Risk of Subarachnoid Hemorrhage

Roelof Risselada, H Straatman, Fop Kooten, Diederik Dippel, Aad van der Lugt, Wiro Niessen, Azadeh Firouzian, RMC (Ron) Herings, MCJM Sturkenboom

Research output: Contribution to journalArticleAcademicpeer-review

46 Citations (Scopus)

Abstract

Background and Purpose-Vascular endothelium, which can be affected by statins, is believed to play a substantial role in subarachnoid hemorrhage (SAH). Our objective was to estimate the association between use and withdrawal of statins and the risk of SAH. Methods-We conducted a population-based case-control study within the PHARMO database. A case was defined as a person hospitalized for SAH (ICD-9-CM code 430) in the period January 1, 1998 to December 31, 2006. Ten randomly chosen controls were matched to each case on age, gender, and calendar date. Results-During the study period 1004 incident cases of SAH were identified. Current use of statins did not significantly decrease the risk of SAH (OR = 0.77, 95% CI 0.55 to 1.07). The odds ratio for recent withdrawal compared to nonusers was 1.62 (95% CI 0.96 to 2.73). Compared to current use, recent withdrawal was associated with an increased risk of SAH (OR = 2.34, 95% CI 1.35 to 4.05). Interaction analysis showed that the effect of statin withdrawal was highest in patients who had also recently stopped antihypertensive drugs (OR = 6.77, 95% CI 2.10 to 21.8). Conclusions-Current use of statins seems to lower the risk of SAH, although the reduction was not significant in new users. Statin withdrawal increased the risk of SAH by a factor 2, even more in patients who had also recently stopped their antihypertensive treatment. (Stroke. 2009; 40: 2887-2892.)
Original languageUndefined/Unknown
Pages (from-to)2887-2892
Number of pages6
JournalStroke
Volume40
Issue number8
DOIs
Publication statusPublished - 2009

Research programs

  • EMC NIHES-05-63-02 Quality
  • EMC COEUR-09
  • EMC NIHES-03-30-01
  • EMC NIHES-03-30-03
  • EMC NIHES-03-77-02

Cite this